| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 264.16 | 4.6% | 5.1% |
| Total Income | 264.16 | 4.6% | 5.1% |
| Expenditure | 241.12 | 3.4% | 7.8% |
| PBT | 5.77 | 87.3% | 338.4% |
| Net Profit | 2.75 | 59.9% | 138.0% |
| OPM | 8.72% | 1.03pp | 2.29pp |
| NPM | 1.04% | 0.36pp | 3.91pp |
| EPS | 0.03 | 50.0% | 130.0% |
Lumexa Imaging Announces Q2 2026 Results
13 Aug 2026 · 13 Aug, 1:40 am
Summary
Lumexa Imaging reported second quarter 2026 consolidated revenues of $264.2 million, a 5.1% increase year-over-year. The company achieved a net income of $2.7 million, a substantial turnaround from a net loss of $7.2 million in the prior year's second quarter. While Adjusted EBITDA remained stable at $56.4 million, the Adjusted EBITDA margin slightly decreased to 21.4% from 22.4%. Management highlighted strong same-center growth and expansion of advanced imaging services. The company reiterated its full-year revenue guidance and narrowed its Adjusted EBITDA guidance range.
Key Highlights
- 1
Consolidated revenues reached $264.2 million in the second quarter of 2026, marking a 5.1% increase from $251.4 million in the prior year period.
- 2
The company reported a net income of $2.7 million for Q2 2026, a significant improvement from a net loss of $7.2 million in the same quarter of 2025.
- 3
Adjusted EBITDA was $56.4 million in Q2 2026, largely flat compared to $56.3 million in Q2 2025, with an Adjusted EBITDA margin of 21.4% compared to 22.4%.
- 4
Consolidated advanced outpatient volume grew by 6.8% and system-wide advanced volume grew by 6.3% in Q2 2026.
- 5
Same-center advanced outpatient volume growth was 5.2% consolidated and 4.9% system-wide in Q2 2026.
- 6
GAAP EPS was $0.03 per share and Adjusted EPS was $0.20 per share for the second quarter of 2026.
- 7
The company reiterated its full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.
Management Comments
Caitlin Zulla
During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers. Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months. With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.
Informational and educational content only. Not investment advice.